News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InfaCare Names John R. Post COO; Company Focus On Neonatal And Pediatric Therapeutics


10/19/2005 5:11:28 PM

NEPTUNE, N.J., May 20 /PRNewswire/ -- Dr. Robert A. Vukovich, Chairman and Founder of InfaCare Pharmaceutical Corporation, announced today that John R. Post has joined the Company as Chief Operating Officer. InfaCare is a sister company to WellSpring Pharmaceutical Corporation in Neptune, NJ.

"The Board of Directors is extremely pleased with this appointment," said Dr. Vukovich. "John's general management, marketing and sales background provides an ideal blend of operational experience which will allow him to provide the strategic leadership InfaCare now requires. Over his 29-year career in the industry, John has acquired extensive experience in the area of new products, from providing commercial perspective in early drug development to preparing and executing new product launches. We are delighted at John's decision to join InfaCare and look forward to his leadership at an exciting time in the company's development."

John's entire career has been spent in the pharmaceutical industry where he successfully served the interests of Pfizer Inc. and Boehringer Ingelheim Pharmaceuticals Inc. John comes to InfaCare from Pfizer where he served most recently as Area President, Europe/Africa/Middle East/Canada for their Animal Health Division. Other positions held at Pfizer include Vice President, Marketing; Vice President, US Livestock Division; General Manager, Canadian Operations, as well as a variety of sales and marketing positions within the human pharmaceutical division. While at Boehringer Ingelheim, John served in a variety of senior marketing positions, ultimately heading up the US marketing operation. Mr. Post received his BA in Zoology from the University of Santa Barbara.

Commenting on his appointment, Mr. Post said, "I am joining a very exciting company whose future prospects look very promising. I look forward to the opportunity to deliver new and innovative treatments that meet the unmet needs of neonatal and pediatric patients."

InfaCare Pharmaceuticals intends to become the leading provider of innovative therapies for neonates, infants, and older children, as well as a strong force in the maternal healthcare arena. By providing safe, effective, and pharmacoeconomic drug therapies, InfaCare products help to enhance patient quality of life and reduce the associated costs of healthcare. The Company intends to develop stannsoporfin, an injectable inhibitor of heme oxygenase, for the treatment of hyperbilirubinemia in neonates (elevated bilirubin levels leading to jaundice and neurologic damage). Other products in the pipeline include an agent for treatment of infantile GERD (gastroesophageal reflux disease), another for neonatal ileus, and a third for the treatment of bronchopulmonary dysplasia. The Company is also developing a synthetic lung surfactant for the treatment of neonatal respiratory distress syndrome. InfaCare has been privately funded and will soon engage an investment banker in order to complete private financing en route to an initial public offering of common stock.

Contact: Pat Naffin Tel: (732) 938-5885 Fax: (732) 751-9328 Website: http://www.infacarepharm.com/

InfaCare is a new, privately held pharmaceutical company founded in 2001 by Dr. Robert A. Vukovich, the firm's CEO and Chairman. Dr. Vukovich previously founded and managed Roberts Pharmaceutical Corporation of Eatontown, NJ until its acquisition by Shire Pharmaceutical Group in 1999. He is also the founder and CEO of WellSpring Pharmaceutical Corporation of Neptune, NJ. InfaCare received its marketing rights to Stanate(TM) from WellSpring. WellSpring originally licensed worldwide rights to Stanate(TM) from Rockefeller University, New York, NY.

InfaCare Pharmaceutical Corporation

CONTACT: Pat Naffin for InfaCare Pharmaceutical Corporation,+1-732-938-5885, Fax: +1-732-751-9328


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES